Síndrome de Schnitzler tratado con canakinumab
El síndrome de Schnitzler es un raro trastorno caracterizado por rash urticariano crónico y gammapatía monoclonal, acompañado de fiebre intermitente, artralgias o artritis, dolor óseo y linfadenopatías, en el cual la interleuquina 1 (IL-1) tiene un papel preponderante. Se presenta el caso de un var...
Main Author: | Pablo Finucci Curi |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedad Argentina de Reumatologia
2019-09-01
|
Series: | Revista Argentina de Reumatología |
Subjects: | |
Online Access: | https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/445 |
Similar Items
-
Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023-12-01) -
Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
by: Simon Bossart, et al.
Published: (2023-03-01) -
A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
by: Yuya Fujita, et al.
Published: (2021-03-01) -
Schnitzler syndrome: A review of literature, the authors’ observation, and experience with the interleukin-1 inhibitor canakinumab
by: S O Salugina, et al.
Published: (2017-11-01) -
Therapy resistant urticaria as a long-term symptom of an incomplete Schnitzler syndrome
by: Viktoria Puxkandl, et al.
Published: (2023-07-01)